Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
Daiichi Sankyo said on February 19 that EU regulators have accepted for review an application to expand the use of its antibody drug conjugate Enhertu (trastuzumab deruxtecan) for HER2-positive early breast cancer.The European Medicines Agency (EMA) will review the therapy…
To read the full story
Related Article
- Enhertu Reels in EU OK for Adjuvant Use in HER2 Breast Cancer
October 28, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
- EU Panel Backs Enhertu for Adjuvant Use in HER2-Positive Breast Cancer
September 24, 2026
- Enhertu Now under US Review for Post-Neoadjuvant HER2 Breast Cancer
March 10, 2026
- Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
March 2, 2026
BUSINESS
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
- Santen’s Myopia Drug Bags Approval in South Korea
November 4, 2026
- Daiichi Sankyo H1 Revenue Zooms 20% as ADCs Drive Growth
November 2, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…